Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 5 of the 13 calendar months from Oct 2025 to Oct 2026: Dec 2025, Feb 2026, Apr 2026, May 2026 and Sep 2026.
- Largest single sale: $4.1M (65,104 shares) of Travere Therapeutics, Inc. on Sep 16, 2026. Filing
- Last sale before this period: May 5, 2025.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | Chief Research Officer | Feb 15, 2017 | Sep 17, 2026 |
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Sep 16, 2026, Travere Therapeutics, Inc.: sold 112,850 shares for $7.1M, under a disclosed plan; 112,850 shares acquired by exercising options. 1 filing: 1
- Sep 15, 2026, Travere Therapeutics, Inc.: sold 96,198 shares for $6.0M, under a disclosed plan; 78,650 shares acquired by exercising options. 1 filing: 1
- May 6, 2026, Travere Therapeutics, Inc.: sold 2,763 shares for $121K, under a disclosed plan. 1 filing: 1
- May 4, 2026, Travere Therapeutics, Inc.: 4,250 shares vested. 1 filing: 1
- Apr 22, 2026, Travere Therapeutics, Inc.: sold 9,100 shares for $356K, under a disclosed plan. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.